Benzinga | Nov 2, 2021 11:26AM EDT

Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting

* Galecto Inc (NASDAQ:GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC:RHHBY) to explore the combination of GB1211 in a planned Phase 2a trial in non-small-cell lung cancer (NSCLC).

* Under the agreement terms, Galecto will fund and conduct a Phase 2a trial to investigate the combination of GB1211 and Roche's atezolizumab (Tecentriq) for the treatment of first-line NSCLC.

* The Company plans to initiate the Phase 2a combination study during 1H of 2022 and anticipate topline data in mid-2023.

* The phase 2a trial of GB1211 in combination with Tecentriq will be a 1:1 randomized, double-blind, placebo-controlled trial in up to 70 patients.

* The trial is designed to evaluate safety and tumor shrinkage; additionally, it will explore tumor response, clinical activity, and immune biomarkers.

* Price Action: GLTO shares are down 1.78% at $3.31 during the market session on the last check Tuesday.